Test Subjects Sought For Impressive New Breast Cancer Drug

Trastuzumab is the front-line drug used to treat women whose tumors overproduce a growth-regulating protein called Her-2. Trastuzumab blocks the Her-2 receptor on cancer cells and inhibits its signaling, thereby shrinking or stabilizing the tumor.

But nearly one-third of tumors with Her-2 over-expression do not respond to trastuzumab, said Blackwell. In the current trial, the majority of patients — 59 percent — had progressed through three, four or five traditional cancer drugs.

Lapatinib represents a new type of therapy because it targets Her-2 plus another growth factor protein called Epidermal Growth Factor (EGFR). “Blocking the action of two growth factors has a more profound effect on inhibiting cell growth than blocking a single growth factor, and we think this dual action on breast cancer cells is responsible for the positive effects we’re seeing,” said Blackwell. The study was funded by GlaxoSmithKline, the maker of lapatinib.

One thought on “Test Subjects Sought For Impressive New Breast Cancer Drug”

  1. .
    …but the headline “Test Subjects Sought For Impressive New Breast” leapt out at me, because on my front page, the words “Cancer Drug” were on the second line. This was almost one of those Jay Leno headlines…

    As for cancer itself, I think it’s only a few short years until there are cures.

    jon

Comments are closed.